During the last session, Fortress Biotech Inc (NASDAQ:FBIO)’s traded shares were 0.78 million, with the beta value of the company hitting 1.75. The 52-week high for the FBIO share is $4.43, that puts it down -133.16 from that peak though still a striking 34.74% gain since the share price plummeted to a 52-week low of $1.24. The company’s market capitalization is $52.37M, and the average intraday trading volume over the past 10 days was 0.59 million shares, and the average trade volume was 520.45K shares over the past three months.
Fortress Biotech Inc (FBIO) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. FBIO has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 1 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.59.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Fortress Biotech Inc (NASDAQ:FBIO) trade information
The stock’s 5-day price performance is 2.70%, and it has moved by 18.01% in 30 days. Based on these gigs, the overall price performance for the year is 13.10%. The short interest in Fortress Biotech Inc (NASDAQ:FBIO) is 2.57 million shares and it means that shorts have 2.99 day(s) to cover.
Fortress Biotech Inc (FBIO) estimates and forecasts
Statistics show that Fortress Biotech Inc has outperformed its competitors in share price, compared to the industry in which it operates. Fortress Biotech Inc (FBIO) shares have gone up 8.57% during the last six months, with a year-to-date growth rate more than the industry average at 68.71% against 17.10. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 37.20% this quarter and then jump 42.20% in the quarter after that. In the rating firms’ projections, revenue will decrease -3.50% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 32.22M as predicted by 2 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 21.42M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 34.75M and 19.95M respectively. In this case, analysts expect current quarter sales to shrink by -7.30% and then jump by 7.40% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 22.28%. While earnings are projected to return 63.40% in 2024, the next five years will return 25.50% per annum.
FBIO Dividends
Fortress Biotech Inc is due to release its next quarterly earnings on 2024-Nov-12. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Fortress Biotech Inc (NASDAQ:FBIO)’s Major holders
Fortress Biotech Inc insiders own 21.21% of total outstanding shares while institutional holders control 14.56%, with the float percentage being 18.48%.
